← Human Trials & Peer-Reviewed Studies
Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin
Plain-language guide to NCT07552493: not phased randomized trial of Goserelin, 64 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07552493
- Phase
- not phased
- Status
- not yet recruiting
- Start
- 2026-05-01
- Completion (planned or actual)
- 2027-05-01
- Participants
- 64 (estimated)
- Design
- randomized, open label (everyone knows who gets what), prevention
- Conditions studied
- Ovarian Insufficiency; Autologous Hematopoietic Stem Cell Transplantation
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered not phased trial tested Goserelin.
This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female hematologic patients aged 14 to 50 years scheduled for autologous hematopoietic stem cell transplantation (auto-HSCT).
Participants will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group.
The conditioning regimen for autologous hematopoietic stem cell transplantation primarily employs melphalan.
It had two arms (groups): Goserelin group (experimental) and Control group (no intervention).
The registry classes the interventions as drug.
Who Took Part
64 planned participants were the target.
It was open to women only aged from 14 years up to 50 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
How the Study Was Run
It was run as a randomized, parallel-group and open-label study.
Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.
The Goserelin group and the comparison group ran side by side rather than switching.
Everyone knew when Goserelin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
It started in 2026-05-01 with completion listed for 2027-05-01.
It ran at 5 sites in China (5).
Its stated primary purpose is prevention.
What Was Measured
The main thing measured (primary outcome): Menstrual recovery rate six months after transplantation (time frame: month 6).
It also tracked 1 secondary outcome, for example Ovarian function; Safety.
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of Goserelin in 64 people.
Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Goserelin compound page, all human trials.
Our Notes on the Compound
Goserelin: A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.